Leerink upgraded Spruce Biosciences (SPRB) to Outperform from Market Perform with a $160 price target After receiving Breakthrough Therapy Designation, the shares traded up to almost $200 in October 2025. After conducting a $50M PIPE, the stock has traded down to a more attractive valuation, the firm notes. Leerink is intrigued by the late-stage ERT – tralesinidase alfa – for mucopolysaccharidosis type IIIB, especially with shares trading lower than 1.0-time the firm’s peak revenue opportunity.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences upgraded to Outperform from Market Perform at Leerink
- Biotech Alert: Searches spiking for these stocks today
- Spruce Biosciences price target raised to $259 from $254 at Citizens JMP
- Spruce Biosciences Reports Q3 2025 Financial Results
- Spruce Biosciences reports Q3 EPS (14.58) vs. ($15.75) last year